


IFW 1626

| | | | | | |
|---|-------------|----------|--------------|-------------------------|------------------|
| TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) | | | | Docket No. RLL-544US | |
| In Re Application Of: PALLE et al | | | | | |
|  | | | | | |
| Application No. | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No. |
| 10/596,059 | 5/26/2006 | Unknown | 26,815 | Unknown | 1271 |
| Title: PHOSPHODIESTERASE INHIBITORS | | | | | |
| <p>Address to:</p> <p>Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> <p>37 CFR 1.97(b)</p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p style="text-align: center;">37 CFR 1.97(c)</p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p style="margin-left: 40px;"><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center;">OR</p> <p style="margin-left: 40px;"><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p> | | | | | |

| TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) | | | | Docket No. RLL-544US | |
|--|---------------------------------|----------------------------|-------------------------------|----------------------------------|---------------------------------|
| In Re Application of: PALLE et al. | | | | | |
| Application No. 10/596,059 | Filing Date 5/26/2006 | Examiner Unknown | Customer No. 26,815 | Group Art Unit Unknown | Confirmation No. 1271 |
| Title: PHOSPHODIESTERASE INHIBITORS | | | | | |
| <div style="text-align: center;">Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))</div> <div style="margin-top: 10px;"><input type="checkbox"/> A check in the amount of _____ is attached. <input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <u>50-0912</u> as described below.<div style="margin-left: 40px;"><input type="checkbox"/> Charge the amount of _____ <input type="checkbox"/> Credit any overpayment. <input checked="" type="checkbox"/> Charge any additional fee required.</div></div> <div style="margin-top: 10px;"><input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.</div> <div style="margin-top: 10px;">WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</div> <div style="display: flex; justify-content: space-between; margin-top: 20px;"><div style="width: 45%;"><div style="text-align: center; border-bottom: 1px solid black; margin-bottom: 5px;">Certificate of Transmission by Facsimile*</div><div style="border: 1px solid black; padding: 5px; min-height: 150px;"><p>I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa</p><div style="border-top: 1px solid black; margin-top: 20px; text-align: center;">(Date)</div><div style="border-top: 1px solid black; margin-top: 20px; text-align: center;">Signature</div><div style="border-top: 1px solid black; margin-top: 20px; text-align: center;">Typed or Printed Name of Person Signing Certificate</div></div></div><div style="width: 45%;"><div style="text-align: center; border-bottom: 1px solid black; margin-bottom: 5px;">Certificate of Mailing by First Class Mail</div><div style="border: 1px solid black; padding: 5px; min-height: 150px;"><p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on</p><div style="border-top: 1px solid black; margin-top: 20px; text-align: center;">5/4/2007 (Date)</div><div style="border-top: 1px solid black; margin-top: 20px; text-align: center;"> Signature of Person Mailing Correspondence Christine Kenedy-Renner</div><div style="border-top: 1px solid black; margin-top: 20px; text-align: center;">Typed or Printed Name of Person Mailing Certificate</div></div></div></div> <div style="margin-top: 20px;"><div style="display: flex; justify-content: space-between;"><div style="width: 45%;"><p>*This certificate may only be used if paying by deposit account.</p><div style="border-top: 1px solid black; margin-top: 20px; text-align: center;"> Signature</div><div style="margin-top: 10px;">George E. Heibel, Esq. Reg. No. 42,648</div><div style="margin-top: 20px;">CUSTOMER NO. 26815</div></div><div style="width: 45%; text-align: right;"><div style="margin-top: 20px;">Dated: 5/4/2007</div></div></div></div> <div style="margin-top: 20px;">CC:</div> | | | | | |

| | | |
|--|---------------------------------|------------------------|
| INFORMATION DISCLOSURE CITATION | Docket No.: RLL-544US | Serial No.: 10/596,059 |
| | Applicants: PALLE <i>et al.</i> | |
| | Filed: 5/26/2006 | Group: |



| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----|-----------------|------------|--------------|-------|----------|----------------------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | A1 | 5,686,434 | 11/11/1997 | Kleinman | 514 | 92 | |
| | A2 | 5,869,511 | 2/9/1999 | Cohan et al. | 514 | 378 | |
| | A3 | 6,114,367 | 9/5/2000 | Cohan et al. | 514 | 378 | |
| | | | | | | | |


| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|----|-----------------|------------|---------|-------|----------|-------------------------|
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES NO |
| | B1 | DE 199 09 785 | 9/7/2000 | Germany | C07D | 413/04 | |
| | B2 | WO 95/14680 | 6/1/1995 | PCT | C07D | 261/04 | |
| | B3 | WO 95/14681 | 6/1/1995 | PCT | C07D | 261/04 | |
| | B4 | WO 95/24398 | 9/14/1995 | PCT | C07D | 261/04 | |
| | B5 | WO 02/081447 | 10/17/2002 | PCT | C07D | 209/46 | |
| | B6 | WO 02/100332 | 12/19/2002 | PCT | A61K | | |
| | | | | | | | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|--|---|--|
| C1 | Sutherland and Rall, "The Relation of Adenosine-3' ,5'-Phosphate and Phosphorylase to the Actions of Catecholamines and Other Hormones", <i>Pharmacological Reviews</i> , <u>12</u> :265-299 (1960) | |
| C2 | Beavo and Reifsnnyder, "Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors", <i>Trends in Pharmacological Sciences</i> , <u>11</u> :150-155 (1990) | |
| C3 | Nicholson et al., "Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes", <i>Trends in Pharmacological Sciences</i> , <u>12</u> :19-27 (1991) | |
| C4 | Verghese et al, "Anti-Neutrophil Activity of Cyclic Nucleotide Phosphodiesterase Inhibitors with Varying Cardiotonic Potencies", <i>Journal of Molecular Cell Cardiology</i> , <u>12</u> (suppl. II):S61 (1989) | |
| C5 | T.J. Trophy, " <i>Directions for new Anti-Asthma Drugs</i> ", 37, eds. S.R. O Donnell and G.A. Perssan, Birkheuserverlag (1988) | |

| | |
|----------|-----------------|
| EXAMINER | DATE CONSIDERED |
|----------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | |
|--|---------------------------------|------------------------|
| INFORMATION DISCLOSURE CITATION | Docket No.: RLL-544US | Serial No.: 10/596,059 |
| | Applicants: PALLE <i>et al.</i> | |
| | Filed: 5/26/2006 | Group: |



| | |
|-----|---|
| C6 | Ashton et al., "Selective Type IV Phosphodiesterase Inhibitors as Antiasthmatic Agents. The Syntheses and Biological Activities of 3-(Cyclopentyloxy)-4-methoxybenzamides and Analogues", <i>Journal of Medicinal Chemistry</i> , <u>37</u> (11):1696-1703 (1994) |
| C7 | DiSanto and Heaslip, "Identification and Stabilization of Large Molecular Weight PDE-IVs from U937 Cells", <i>Biochemical and Biophysical Research Communications</i> , <u>197</u> (3):1126-1131 (1993) |
| C8 | Greene and Wuts, <i>Protective Groups in Organic Synthesis</i> . 2nd ed. New York:John Wiley and Sons. |
| C9 | Molina and de Aguiar, "Synthesis of new 4,5-dihydroisoxazoles with potential anti-inflammatory activity," <i>Heterocyclic Communications</i> , <u>9</u> (5):535-538 (2003) |
| C10 | Rai and Hassner, "Intermolecular 1,3-dipolar cycloaddition of nitrile oxides with vinyl acetate and acrylonitrile," <i>Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry</i> , <u>36B</u> (3):242-245 (1997) - Abstract Only |
| C11 | Fihi et al, "Reaction des methylene γ -butyrolactones avec les arylnitriloxides. Evolution inattendue du bisadduit issu de la 5-methylene(5H)furan-2-one", <i>Bulletin des Societes Chimiques Belges</i> , <u>104</u> (1):55-62 (1995) - No translation |
| C12 | Rai et al., "A Convenient Method of the Generation of Nitrile Oxide and its Application to the Synthesis of 2-Isloxazolines", <i>Organic Preparations and Procedures International</i> , <u>24</u> (1):91-94 (1992) |
| C13 | Al-Timari and Fišera, "Regioselective synthesis of C-nucleosides by 1,3-dipolar cycloaddition of aryl nitrile oxides to 5,6-dideoxy-1,2-O-isopropylidene- α -D-xylo-hex-5-enofuranose", <i>Carbohydrate Research</i> , <u>218</u> :121-127 (1991) |
| C14 | Clerici et al., "Isothiazole Dioxides: Synthesis and Inhibition of <i>Trypanosoma brucei</i> Protein Farnesyltransferase", <i>Bioorganic & Medicinal Chemistry Letters</i> , <u>12</u> (16):2217-2220 (2002) |
| C15 | Hafez et al., "New pyrazolines, isoxazolines and sulfides from 4,7-dimethoxy-5-acetyl-6-hydroxybenzofuran (Khellinone) and their antimicrobial activities", <i>Pakistan Journal of Scientific and Industrial Research</i> , <u>33</u> (5-6):197-200 (1990) - Abstract Only |
| C16 | Khalil et al., "Synthesis and microbial activity of 5-heterocyclo-8-hydroxyquinolines", <i>Journal of the Indian Chemical Society</i> , <u>67</u> (10):821-823 (1990) - Abstract Only |
| C17 | Koroleva et al., "Cycloreversion of 5-(4-pyridyl)-2-isoxazolines in reactions with bases", <i>Russian Journal of Organic Chemistry</i> , <u>33</u> (1):108-112 (1997) (Translation of Zhurnal Organicheskoi Khimii - Abstract Only) |
| | |

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |